Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has received an average rating of “Moderate Buy” from the eight research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $33.33.

A number of brokerages have issued reports on CRVS. Weiss Ratings raised Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. LADENBURG THALM/SH SH raised shares of Corvus Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, July 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, September 16th.

Get Corvus Pharmaceuticals alerts:

View Our Latest Analysis on CRVS

Institutional Trading of Corvus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of CRVS. Tidal Investments LLC boosted its position in Corvus Pharmaceuticals by 26.4% during the second quarter. Tidal Investments LLC now owns 136,276 shares of the company’s stock valued at $2,036,000 after acquiring an additional 28,501 shares during the last quarter. Engineers Gate Manager LP bought a new position in shares of Corvus Pharmaceuticals in the 2nd quarter worth about $538,000. Integrated Wealth Concepts LLC bought a new position in shares of Corvus Pharmaceuticals in the 2nd quarter worth about $122,000. Arizona State Retirement System acquired a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at about $260,000. Finally, Braidwell LP lifted its stake in shares of Corvus Pharmaceuticals by 21.3% in the 2nd quarter. Braidwell LP now owns 2,126,298 shares of the company’s stock valued at $31,767,000 after purchasing an additional 373,500 shares during the period. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS opened at $10.90 on Monday. Corvus Pharmaceuticals has a 12-month low of $6.39 and a 12-month high of $26.95. The stock has a market cap of $916.91 million, a PE ratio of -17.87 and a beta of 1.44. The business has a 50 day moving average of $13.51 and a 200-day moving average of $13.84.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). Equities research analysts expect that Corvus Pharmaceuticals will post -0.79 earnings per share for the current year.

About Corvus Pharmaceuticals

(Get Free Report)

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that modulate the immune system to treat cancer and other serious diseases. The company’s research is centered on therapies designed to influence immune-cell signaling and activity, with the goal of improving the body’s ability to respond to disease.

Corvus’ leading investigational product is soquelitinib, formerly known as CPI-818. It is an oral, selective inhibitor of inducible T-cell kinase (ITK) being studied for the treatment of T-cell lymphomas and potentially other cancers.

Recommended Stories

• Five stocks we like better than Corvus Pharmaceuticals
• Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
• The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It
• McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers?
• MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.